The drug supervision system has another heavy lawsuit chief Wang Lifeng sacked

On the evening of August 23, 2018, the official website of the State Administration for Market Regulation announced that Wang Lifeng, the former director of the Drug and Cosmetic Registration Management Department of the State Food and Drug Administration (the Department of Traditional Chinese Medicine and Ethnic Medicine Supervision), is suspected of serious violations of discipline and law, and is currently undergoing disciplinary review and investigation.Supervision and investigation.

Since August 16, when the central government launched the strongest accountability for the Changchun Changsheng company's problematic vaccine case, eight officials from the former State Food and Drug Administration (National Drug Administration) have been dealt with.

Among them, Wang Lifeng and Wu Zhen, a member of the party group and deputy director of the former State Food and Drug Administration, were announced to be investigated;6 people were dismissed.

In addition, Jiao Hong, director of the State Food and Drug Administration, was ordered to conduct an in-depth inspection.Wang Lifeng is Wu Zhen's old subordinate, and the two have worked together for many years.

In 2006, Wu Zhen was transferred from the post of director of the Jiangxi Provincial Drug Administration to the deputy director of the State Food and Drug Administration.Since then, he has been in charge of drug registration, supervision, and review for a long time, and the vaccine industry is also under his charge.Until the start of the current round of party and state institutional reforms in March this year, the Food and Drug Administration was integrated into the State Administration for Market Regulation. Wu Zhen, who was 60 years old at the time, did not hold a post in the State Administration for Market Regulation. According to media reports, he had retired.

According to public reports, as early as 2009, Wang Lifeng had served as the director of the Inspection Bureau of the State Food and Drug Administration.Around 2013, he was transferred to the director of the Drug and Cosmetic Registration Department of China Food and Drug Administration.After the Food and Drug Administration was merged into the State Administration for Market Regulation in March this year, he continued to serve as the director of the Drug and Cosmetic Registration Management Department of the State Drug Administration.

It can be seen that the inspection, drug and cosmetic registration and other businesses that Wang Lifeng is responsible for are all within the scope of Wu Zhen's responsibility.

According to public information, Wang Lifeng accompanied Wu Zhen several times to investigate and attend press conferences.In August 2015, the State Council Information Office held a press conference on the reform of the drug and medical device review and approval system. Wang Lifeng and Wu Zhen attended and answered questions from reporters.

In addition, in 2011, the State Food and Drug Administration issued a notice to remove Wu Zhen from the post of secretary-general of the National Pharmacopoeia Commission, and Wang Lifeng took over the post.

To sum up, Wang Lifeng has served as the director of the Drug and Cosmetic Registration Management Department for at least five years.

According to the information released by the former State Food and Drug Administration, one of the responsibilities of the Drug and Cosmetic Registration Management Department is to undertake the evaluation of the quality management system of vaccine supervision and the administrative protection of pharmaceuticals.

In March 2013, Wang Lifeng accepted an exclusive interview, responded to questions about the slow speed of drug review, and talked about the issue of vaccine review.

He said: drug review is a scientific issue, the core of which is to ensure the safety and effectiveness of drugs.For example, vaccines are preventive medicines that belong to healthy people and must be 100% safe.Therapeutic drugs must have certain side effects. Therefore, we must evaluate its risks and benefits. If the benefits outweigh the side effects, we will approve it.For life-saving medicines, such as medicines for the treatment of cancer, even though the medicines have side effects, as long as they are effective in treating the disease, we will approve them.Therefore, the most important thing in the drug review stage is to grasp the effectiveness and safety of the drug.

After the incident of labeling vaccines in Shanxi broke out in 2010, the Ministry of Health and the State Food and Drug Administration held a press conference in April of that year.At that time, the personnel adjustment of the drug supervision system was frequent. At the press conference, a reporter asked whether the personnel adjustment was related to the vaccine incident?

Wang Lifeng was the director of the Inspection Bureau of the State Food and Drug Administration at the time. He responded at the time: Everyone has paid attention to vaccines recently, which is right. There are a lot of news about vaccines disclosed on the Internet.Together, there is actually little correlation between these pieces of information.Corruption has nothing to do with vaccines.